Evidence map›Paper›PMID 40657303›Full record

ArticleHemaSphere2025

Predicting thrombotic risk in patients with classical Hodgkin lymphoma: Thro-HL multicenter study.

Giovanni Manfredi Assanto, Eleonora Alma, Alessandro Cellini, Giovanni Marsili, Gianluca Maiorana, Cristina Santoro, Martina Salvatori, Natalia Cenfra, Vladimir Otasevic, Darko Antic and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Giovanni Manfredi AssantoDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.ORCID https://orcid.org/0000-0002-6190-9635
Eleonora AlmaDipartimento di scienze di laboratorio ed ematologiche, IRCCS Policlinico Gemelli Università Cattolica del Sacro Cuore Rome Italy.
Alessandro CelliniDepartment of Medicine DIMED Hematology Unit Padova Italy.
Giovanni MarsiliGIMEMA Foundation Rome Italy.
Gianluca MaioranaDepartment of Clinical and Molecular Medicine, Hematology Unit University Hospital Sant' Andrea - Sapienza Rome Italy.
Cristina SantoroDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Martina SalvatoriDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Natalia CenfraHematology Unit S. Maria Goretti Hospital, AUSL Latina Latina Italy.
Vladimir OtasevicClinic for Hematology University Clinical Center of Serbia Belgrade Serbia.
Darko AnticClinic for Hematology University Clinical Center of Serbia Belgrade Serbia.
Gianna Maria D'EliaDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Maria Paola BianchiDepartment of Clinical and Molecular Medicine, Hematology Unit University Hospital Sant' Andrea - Sapienza Rome Italy.
Giorgia AnnechiniDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Silvio LigiaDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Alessandro PulsoniDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Agostino TafuriDepartment of Clinical and Molecular Medicine, Hematology Unit University Hospital Sant' Andrea - Sapienza Rome Italy.
Andrea VisentinDepartment of Medicine DIMED Hematology Unit Padova Italy.ORCID https://orcid.org/0000-0003-0271-7200
Alfonso PiciocchiGIMEMA Foundation Rome Italy.
Stefan HohausHematology, IRCCS Policlinico Gemelli Università Cattolica del Sacro Cuore Rome Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.
Ilaria Del GiudiceDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.ORCID https://orcid.org/0000-0001-6864-9533
Antonio ChistoliniDepartment of Translational and Precision Medicine, Hematology Sapienza University of Rome - AOU Policlinico Umberto I Rome Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombosis Lymphoma (ThroLy) and Khorana scores have been conceived to predict the thrombotic risk in oncohematologic patients. Currently, there is no univocal indication to perform thromboprophylaxis in classical Hodgkin lymphoma (cHL). We performed a retrospective study to validate scores and risk factors in a cohort of consecutive patients with cHL, treated from 2014 to 2022 outside clinical trials. A total of 470 cHL patients without thromboprophylaxis were included, of whom 57 (12%) experienced a thrombotic event (TE) at 3.3 months (range 1-52) from diagnosis. Neither Khorana nor ThroLy score significantly predicted the thrombotic risk. In a multivariate analysis including Throly parameters and other risk factors, an independent prognostic impact on the TE risk was found for bulky disease (3 points), ECOG PS 2-4 (2 points), presence of peripherally implanted central venous catheter (2 points), mediastinal involvement (1 point), which were combined in a new risk model (Thro-HL). Low-risk (score 0-1; 39%,

Identifiers

PMID40657303
PMCPMC12255904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.